Overview
Introduction
Cognitive impairment is regarded as a core deficit of schizophrenia; the primary unmet need is the availability of an effective drug for the treatment of cognitive impairment in schizophrenia (CIS). However manufacturers will need to carefully consider how to develop and market such a drug, and increase awareness of the disorder in patients, carers and prescribers.
Scope
- Analysis of a survey of 185 prescribing psychiatrists in the seven major markets as well as in-depth interviews with CIS Key Opinion Leaders
- Detailed treatment trees showing the prevalence,diagnosis and treatment rates of CIS across the seven major markets
- Analysis of specific treatment strategies to improve cognition once CIS has been diagnosed
- Insight into diagnostic and therapeutic unmet needs, and recommendations to aid market penetration and maximize prescription rates
Report Highlights
According to Datamonitor Primary Physician Research (PPR) CIS is perceived to be prevalent in 60% of the schizophrenia population, although the rate is likely to be even higher. However, CIS is currently diagnosed in fewer than 40% of patients, with a treatment rate which is even lower.
Manufacturers need to increase physician awareness of specifically testing for cognitive impairment during or soon after the initial diagnosis schizophrenia, in order to maximize long-term CIS drug revenues.
In the absence of an approved drug therapy for CIS, treatment primarily consists of atypical antipsychotic therapy. However, numerous drugs are in development for CIS utilizing a variety of drug mechanisms, although Datamonitor believes that it is unlikely that a drug will be approved for CIS in the next five years.
Reasons to Purchase
- Understand the diagnosis and treatment pathways in CIS and asses differential treatment and unmet needs in CIS
- Design patient and physician awareness campaigns based upon patient and advocacy response and commercial analysis
- Enhance development and market penetration strategies of CIS drugs
| 
View Cart
